Injectable glucagon-like peptide-1 receptor agonists have revolutionized the clinical management of type 2 diabetes mellitus and chronic obesity. However, widespread subcutaneous administration introduces unique localized tissue responses. Clinicians now recognize AGLP1-type amyloidosis as an emerging iatrogenic complication at repetitive injection sites. Amyloidosis encompasses a diverse group of pathological disorders marked by extracellular aggregation of rigid, insoluble fibrillar proteins. When therapeutic peptide analogs self-assemble into insoluble beta-pleated sheets locally, they create firm subcutaneous nodules that frequently puzzle practitioners. Consequently, recognizing this localized phenomenon prevents unnecessary alarm and invasive systemic workups.

Pathophysiology and Mechanisms Underlying AGLP1-Type Amyloidosis

Peptide therapeutics inherently carry a biophysical propensity to aggregate under specific microenvironmental conditions. Glucagon-like peptide-1 analogs share substantial structural homology with native human glucagon and related incretin peptides. Repeated subcutaneous injection concentrates high quantities of these engineered peptides within adipose tissue. Over time, physical shear stresses, local pH variations, and physiological body temperatures destabilize native peptide folding. Therefore, partially unfolded intermediate peptides organize into highly ordered oligomers and cross-beta-sheet fibrils. Furthermore, the persistent delivery of drug molecules into identical anatomic areas significantly accelerates nucleation-dependent fibrillogenesis. Pathologists identify classical non-fibrillar matrix components alongside the peptide fibrils, including serum amyloid P component, apolipoprotein E, and glycosaminoglycans. Because liraglutide and adjacent analogs contain lipophilic acyl side chains designed to prolong serum half-life, these lipid moieties may also alter local solubility. As a result, extracellular deposits accumulate indolently, culminating in durable amyloidomas that resist endogenous enzymatic clearance.

Clinical Presentation and the Diagnostic Dilemma

Patients typically present with solitary, painless, firm subcutaneous nodules located across common injection surfaces, most notably the anterior abdominal wall. In a recent landmark case report, a 71-year-old woman presented with an abdominal mass following successive clinical therapies with liraglutide, semaglutide, and tirzepatide. Because patients often switch between various incretin formulations over several years, pinpointing a single causative molecule presents unique challenges. Moreover, physical examination often cannot distinguish these firm amyloid deposits from insulin-induced lipohypertrophy, epidermal inclusion cysts, foreign body granulomas, or localized soft-tissue neoplasms. In many instances, the indolent progression leads clinicians to perform excisional biopsies to rule out occult metastatic malignancy. However, encountering extracellular amyloid matrix unexpectedly shifts diagnostic concern toward life-threatening systemic amyloidosis. Consequently, physicians must obtain a meticulously detailed history of past and present subcutaneous injections whenever assessing ambiguous dermal or subcutaneous nodules.

Histopathological Confirmation and Congo Red Birefringence

Histological evaluation serves as the primary gateway for identifying amyloid deposits within biopsied dermal and adipose tissues. Routine hematoxylin and eosin staining demonstrates abundant amorphous, eosinophilic, and acellular material expanding the subcutis and deep dermis. However, standard light microscopy cannot definitively prove the presence of fibrillar cross-beta sheet architecture. Therefore, pathologists apply Congo red staining to demonstrate characteristic pathognomonic optical properties. Under polarized light microscopy, Congo red-stained tissue reveals diagnostic apple-green birefringence. Additionally, the tissue architecture exhibits persistent congophilia under cross-polarizers, verifying true amyloid aggregation. Nevertheless, confirming amyloid deposition represents only an initial diagnostic step. Pathologists must determine whether the deposit signifies localized drug aggregation or life-threatening systemic disease. Because systemic immunoglobulin light chain amyloidosis carries grim prognostic implications, accurate amyloid typing becomes paramount for patient care and clinical safety.

Role of Mass Spectrometry and Immunohistochemistry

Accurate protein subtyping requires sophisticated analytical techniques beyond routine histopathology. Liquid chromatography-tandem mass spectrometry coupled with laser-capture microdissection serves as the definitive reference standard for amyloid typing. In recent cases of incretin-induced amyloidosis, proteomic analysis revealed a characteristic amyloid signature rich in apolipoproteins along with distinct peptide spectra for liraglutide. Furthermore, immunohistochemistry provides complementary diagnostic utility, demonstrating strong positivity for glucagon within the amyloid matrix. Because liraglutide shares extensive sequence homology with native glucagon, anti-glucagon antibodies cross-react robustly with the aggregated therapeutic peptides. Conversely, diagnostic tests demonstrate complete absence of clonal kappa or lambda immunoglobulin light chains, serum amyloid A, and transthyretin. By definitively demonstrating the drug-related peptide origin, molecular pathology protects patients from misclassification and eliminates the requirement for unnecessary bone marrow examinations.

Clinical Practice Pearls and Injection Site Management

Preventing and managing iatrogenic amyloidosis requires structured patient education and meticulous injection technique. Healthcare providers must actively instruct patients on the absolute necessity of systematic injection site rotation. Injecting repeatedly into identical abdominal quadrants drastically heightens local drug concentrations and dramatically accelerates fibril seeding. Additionally, patients should inspect and palpate their subcutaneous tissue regularly to identify early localized induration. If a nodule develops, clinicians should immediately redirect future injections to alternative anatomical sites, such as the thighs or upper arms. Reassuringly, localized iatrogenic amyloidomas remain entirely benign and lack malignant potential. Asymptomatic lesions generally warrant conservative observation rather than aggressive surgical resections. Most importantly, distinguishing localized deposits from systemic AL amyloidosis spares patients from toxic chemotherapeutic interventions, invasive bone marrow biopsies, and extreme psychological distress.

Frequently Asked Questions

What causes AGLP1-type amyloidosis at subcutaneous injection sites?

AGLP1-type amyloidosis develops when high local concentrations of synthetic glucagon-like peptide-1 receptor agonists misfold into insoluble fibrils within subcutaneous tissue. Repetitive injections into the same anatomical area, shear forces during delivery, and physiological tissue conditions destabilize the peptide. Consequently, the drug molecules self-assemble into persistent beta-pleated sheets, creating an indolent, localized amyloid mass.

How do pathologists distinguish localized amyloidomas from systemic AL amyloidosis?

Pathologists utilize liquid chromatography-tandem mass spectrometry and targeted immunohistochemistry to identify the specific aggregating protein. While systemic AL amyloidosis reveals monoclonal light chains, AGLP1-type deposits display glucagon immunoreactivity and unique incretin peptide spectra. Additionally, bone marrow biopsies, serum free light chain assays, and cardiac imaging remain entirely normal in localized iatrogenic cases.

Should patients permanently discontinue GLP-1 receptor agonists if amyloidosis occurs?

Patients typically do not need to discontinue their metabolic therapy when localized amyloidosis develops. Because the disease process remains entirely local and non-toxic, clinicians advise patients to avoid injecting into or near the affected area. Healthcare providers should retrain patients on strict anatomical rotation protocols across alternative sites, permitting continued metabolic management.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Loggie J et al. Glucagon-Like Peptide-1 Analog-Type Amyloidosis: A Case Report and Review of the Literature. Am J Dermatopathol. 2026 Oct 30. doi: 10.1097/DAD.0000000000003440. PMID: 42961329.
2. Martins CO, Lezcano C, Yi SS, Landau HJ, Chapman JR, Dogan A. Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis. Haematologica. 2018 Dec;103(12):e610-e612. doi: 10.3324/haematol.2018.203000.
3. Vrana JA, Theis JD, Dasari S, et al. Mass Spectrometry Identification of AGLP1 (Glucagon-like Peptide 1 Analog) Amyloidosis: Proteomic Profiling of an Emerging Iatrogenic Entity. Amyloid. 2024;31(2):112-119.